Market Overview

UPDATE: Morgan Stanley Reiterates on Pfizer as Vaccine Pipeline is Under-Appreciated

Share:
Related PFE
$45 Billion Thursday For M&A Shows There Are Still Plenty Of Buyers Out There
Pharma Names Under Pressure Amid Perrigo Warning
Ligand Pharma Adds Tech, Grows On Partners' Success (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Pfizer (NYSE: PFE), and raised the price target from $34.00 to $36.00.

In the report, Morgan Stanley noted, “We believe Pfizer can outperform the pharma group given its potential for positive pipeline news and strategic action. Mgmt is committed to share repurchase and dividend increases. Financial and strategic action should continue to drive shareholder value.”

Pfizer closed on Thursday at $31.12.

Latest Ratings for PFE

DateFirmActionFromTo
Apr 2016Goldman SachsReinstatesNeutral
Apr 2016JP MorganAssumesOverweight
Apr 2016Morgan StanleyAssumesEqual-weight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!